問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

CHANGHUA CHRISTIAN HOSPITAL

List

840Cases

2008-11-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2009-01-01 - 2013-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER)

  • Condition/Disease

    Acute Coronary Symdrome

  • Test Drug

    SCH530348

Participate Sites
13Sites

Terminated13Sites

2010-03-01 - 2012-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2009-09-30 - 2021-10-18

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2009-11-01 - 2011-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2007-05-01 - 2008-12-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2020-05-01 - 2023-02-22

Phase I/II

A Phase 1b/2a, Open-Label Study to Evalute the Safety, Tolerability and Immunogenicity of VTP-300 with or wuthout Nivoulumab in Participants with Chronic Hepatitis B infecttion

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    ChAdOx1-HBV; MVA-HBV; Nivolumab

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2018-08-31 - 2026-05-31

Phase III

A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ADJUVANT ANTHRACYCLINE/TAXANE-BASED CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PATIENTS WITH OPERABLE TRIPLE-NEGATIVE BREAST CANCER

  • Condition/Disease

    Triple-Negative Breast Cancer

  • Test Drug

    Atezolizumab (RO5541267)

Participate Sites
13Sites

Not yet recruiting3Sites

Recruiting1Sites

Terminated9Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

2019-01-01 - 2025-01-31

Phase III

A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIGTM) Versus Alectinib (ALECENSA) in Advanced Anaplastic Lymphoma Kinase-Positive Non--Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib

  • Condition/Disease

    non-small cell lung cancer (NSCLC)

  • Test Drug

    Brigatinib

Participate Sites
7Sites

Recruiting7Sites

2018-10-01 - 2020-08-25

Phase II

A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Ulcerative Colitis

  • Condition/Disease

    Ulcerative Colitis

  • Test Drug

    Filgotinib (GS-6034)

Participate Sites
7Sites

Terminated6Sites

1 57 58 59 60 61 84
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB